Posted inComunicati
Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
COMUNICATO STAMPA - CONTENUTO PROMOZIONALE IN026 is a potential first-in-class mRNA therapy for refractory gout,…









